Alerts will be sent to your verified email
Verify EmailREKVINA LAB.
|
Rekvina Laboratories
|
Cian Healthcare
|
Venmax Drugs&Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
9.93 % | 1.01 % | 1.17 % |
|
5yr average Equity Multiplier
|
6.31 | 3.21 | 0.08 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 0.39 | 0.14 |
|
5yr Avg Net Profit Margin
|
0.0 | -17.41 % | -19.62 % |
|
Price to Book
|
0.0 | 0.0 | 1.42 |
|
P/E
|
0.0 | 0.0 | 82.21 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 55.28 Days | 288.55 Days |
|
Inventory Days
|
0.0 | 219.95 Days | 5.2 Days |
|
Days Receivable
|
0.0 | 224.43 Days | 430.69 Days |
|
Days Payable
|
0.0 | 542.88 Days | 141.12 Days |
|
5yr Average Interest Coverage Ratio
|
-132.32 | -0.81 | -260.56 |
|
5yr Avg ROCE
|
-100.9 % | -0.26 % | -47.43 % |
|
5yr Avg Operating Profit Margin
|
0.0 | 7.22 % | -65.91 % |
|
5 yr average Debt to Equity
|
-0.19 | 1.21 | -0.45 |
|
5yr CAGR Net Profit
|
18.47 % | n/a | -42.57 % |
|
5yr Average Return on Assets
|
-132.46 % | -3.63 % | 199.45 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
41.3 % | 95.0 % | 13.8 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 28.74 % | -9.33 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Rekvina Laboratories
|
Cian Healthcare
|
Venmax Drugs&Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|